Cargando…
Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas
BACKGROUND: In patients with adenocarcinoma of the pancreas, there are no standard second-line regimens. Many pre-clinical studies have shown that metformin alone or when combined with paclitaxel has antitumour effects on this tumour. We have tested here the combination of paclitaxel and metformin f...
Autores principales: | Braghiroli, Maria Ignez, de Celis Ferrari, Anezka C R, Pfiffer, Tulio Eduardo, Alex, Alexandra Kichfy, Nebuloni, Daniela, Carneiro, Allyne S, Caparelli, Fernanda, Senna, Luiz, Lobo, Juliana, Hoff, Paulo Marcelo, Riechelmann, Rachel P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544571/ https://www.ncbi.nlm.nih.gov/pubmed/26316884 http://dx.doi.org/10.3332/ecancer.2015.563 |
Ejemplares similares
-
Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas
por: Ramella Munhoz, Rodrigo, et al.
Publicado: (2013) -
Carcinoid syndrome: update on the pathophysiology and treatment
por: de Celis Ferrari, Anezka C. Rubin, et al.
Publicado: (2018) -
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
por: Gharaibeh, M, et al.
Publicado: (2015) -
Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2021) -
Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2021)